WASHINGTON (AP) — A new strategy to fight an extremely aggressive type of brain tumor showed promise in a pair of experiments with a handful of patients. Scientists took patients’ own immune cells and turned them into “living drugs” able to recognize and attack glioblastoma. In the first-step tests, those cells shrank tumors at least temporarily, researchers reported Wednesday. So-called CAR-T therapy already is used to fight blood-related cancers like leukemia but researchers have struggled to make it work for solid tumors. Now separate teams at Massachusetts General Hospital and the University of Pennsylvania are developing next-generation CAR-T versions designed to get past some of glioblastoma’s defenses. “It’s very early days,” cautioned Penn’s Dr. Stephen Bagley, who led one of the studies. But “we’re optimistic that we’ve got something to build on here, a real foundation.” |
After a strong first round, overall NFL draft ratings down 3 percent from last year'Shardlake' is a TudorTrump hush money trial: What to know as week 2 of testimony opensFraudsters target small businesses with scams. Here are some to watch out forCapitals' T.J. Oshie hopes to play next seasonMaple Leafs star Auston Matthews out for potential elimination matchup with BruinsThe 4 officers killed in North Carolina were tough but kind and loved their jobs, friends sayWhoopi Goldberg fights back tears as The View host defends 'mad' student protestersUS judges reject new Louisiana congressional mapCardinals rally to beat Tigers 2